BMRN
BIOMARIN PHARMACEUTICAL INC
+1.03 (+1.60%)65.77USD361K成交股數12.7B市值168.6本益比(近四季)3.7股價營收比+19.9%營收年增(近四季)2026-10-26下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 990M+20% | 766M+3% | 875M+17% | 776M+9% | 825M+27% | 745M+15% | 746M+28% | 712M+20% | 649M | 646M | 581M | 595M |
| 營業成本 | 203M | 195M | 276M | 140M | 150M | 152M | 188M | 130M | 125M | 138M | 128M | 131M |
| 毛利 | 787M+17% | 571M-4% | 599M+7% | 636M+9% | 675M+29% | 594M+17% | 557M+23% | 582M+25% | 524M | 508M | 453M | 465M |
| 毛利率 | 79.5% | 74.6% | 68.5% | 82.0% | 81.8% | 79.7% | 74.7% | 81.7% | 80.7% | 78.7% | 78.0% | 78.1% |
| 研發費用 | 207M | 179M | 192M | 409M | 161M | 159M | 185M | 184M | 205M | 206M | 191M | 177M |
| 銷售管理費用 | 396M | 258M | 446M | 268M | 232M | 206M | 253M | 263M | 226M | 260M | 216M | 206M |
| 營業利益 | 111M-60% | 130M-42% | −44.6M-139% | −46.7M-139% | 277M+213% | 224M+721% | 114M+273% | 120M+84% | 88.5M | 27.3M | 30.5M | 65.6M |
| 營業利益率 | 11.2% | 16.9% | -5.1% | -6.0% | 33.5% | 30.0% | 15.3% | 16.9% | 13.6% | 4.2% | 5.3% | 11.0% |
| 稅後淨利 | 44.8M-81% | 106M-43% | −46.6M-144% | −30.7M-129% | 241M+171% | 186M+813% | 106M+163% | 107M+91% | 88.7M | 20.3M | 40.4M | 56.0M |
| 淨利率 | 4.5% | 13.8% | -5.3% | -4.0% | 29.1% | 24.9% | 14.2% | 15.1% | 13.7% | 3.1% | 6.9% | 9.4% |
| 稀釋 EPS | 0.23-81% | 0.54-43% | -0.22-140% | -0.16-129% | 1.23+167% | 0.95+850% | 0.55+162% | 0.55+90% | 0.46 | 0.10 | 0.21 | 0.29 |
| 稀釋股數 | 194M | 198M | 197M | 192M | 197M | 196M | 197M | 201M | 199M | 192M | 191M | 195M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 874M | 2.2B | 1.3B | 1.3B | 1.2B | 1.0B | 675M | 972M | 747M | 755M | 785M | 694M |
| 應收帳款 | 1.1B | 904M | 908M | 790M | 856M | 739M | 778M | 691M | 637M | 634M | 572M | 610M |
| 存貨 | 1.8B | 1.3B | 1.3B | 1.4B | 1.3B | 1.3B | 1.2B | 1.2B | 1.1B | 1.1B | 1.0B | 976M |
| 總資產 | 11.7B | 8.6B | 7.6B | 7.6B | 7.5B | 7.1B | 6.9B | 7.1B | 6.9B | 6.8B | 6.8B | 6.6B |
| 有息負債 | 3.5B | 1.4B | 597M | – | – | – | – | – | – | – | – | – |
| 總負債 | 5.4B | 2.4B | 1.5B | 1.6B | 1.4B | 1.4B | 1.4B | 1.8B | 1.8B | 1.9B | 1.9B | 1.8B |
| 股東權益 | 6.3B | 6.2B | 6.1B | 6.1B | 6.0B | 5.8B | 5.4B | 5.3B | 5.1B | 5.0B | 4.9B | 4.8B |
| 負債比 | 46.1% | 27.7% | 19.8% | 20.5% | 19.2% | 18.9% | 21.0% | 25.2% | 26.2% | 27.6% | 27.5% | 27.1% |
| 淨現金(現金 − 有息負債) | −2.7B | 792M | 715M | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 221M+27% | – | – | – | 174M | – | – | 47.0M | – | – | – |
| 資本支出 | – | 20.9M | – | – | – | 16.8M | – | – | 26.1M | – | – | – |
| 自由現金流 | – | 200M+27% | – | – | – | 158M | – | – | 20.9M | – | – | – |
| 折舊攤銷 | – | 16.4M | – | – | – | 22.1M | – | – | 27.4M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 26.1% | – | – | – | 21.2% | – | – | 3.2% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 3.2B
| Reportable | 3.2B | 100.0% | +12.9% |
|---|
產品／服務2025 年度 · 3.6B
| 產品 | 3.2B | 88.9% | +12.8% |
|---|---|---|---|
| ALDURAZYME | 209M | 5.8% | +13.4% |
| KUVAN | 99.5M | 2.8% | -17.7% |
| Royalty And Other | 53.5M | 1.5% | +20.3% |
| ROCTAVIAN | 35.6M | 1.0% | +36.7% |
| VOXZOGO 小計 | 927M | 26.0% | +26.1% |
| VIMIZIM 小計 | 792M | 22.2% | +7.1% |
| NAGLAZYME 小計 | 485M | 13.6% | +1.2% |
| PALYNZIQ 小計 | 433M | 12.2% | +22.0% |
| BRINEURA 小計 | 186M | 5.2% | +10.2% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 3.2B | +12.9% | 349M | 10.8% | 1.80 | 725M |
| FY2024 | 2.9B | +18.0% | 427M | 15.0% | 2.21 | 487M |
| FY2023 | 2.4B | +15.4% | 168M | 6.9% | 0.87 | 62.6M |
| FY2022 | 2.1B | +13.5% | 142M | 6.8% | 0.75 | 54.9M |
| FY2021 | 1.8B | -0.8% | −64.1M | -3.5% | -0.35 | 209M |
| FY2020 | 1.9B | +9.2% | 854M | 45.9% | 4.50 | −28.9M |
| FY2019 | 1.7B | +14.3% | −23.8M | -1.4% | -0.13 | −96.8M |
| FY2018 | 1.5B | – | −77.2M | -5.2% | -0.44 | −124M |